Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

Optic Neuritis: Clinical Features Optic neuritis refers to inflammation of the optic nerve. The term may be used broadly in reference to many causes of optic nerve inflammation including systemic ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

While all large and medium vessel occlusions (up to middle cerebral artery M2 segment) are documented in the GSR, we cannot exclude the possibility that some of the patients with ICA-I and ICA-E had ...

Blogging Stroke highlights high-impact studies published in the journal Stroke. In addition to article summaries, Blogging Stroke includes interviews with authors of recently published Stroke articles ...